Incretin therapy and its effect on body weight in patients with diabetes

Primary Care Diabetes

Volumn 6, Issue 3, 2012, Pages 187-191

  Lind, Marcus ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UDDEVALLA HOSPITAL   (Sweden)

Author keywords

Body weight; Dipeptidyl peptidase 4 (DPP 4) inhibitor; Glucagon like peptide 1 (GLP 1) receptor agonist; Incretin therapy

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE;

BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DECREASED APPETITE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPERTENSION; INSULIN RELEASE; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SATIETY; STOMACH EMPTYING; TREATMENT OUTCOME; WEIGHT REDUCTION;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; TREATMENT OUTCOME;

EID: 84865737941     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2012.04.006     Document Type: Review

References (38)

1. M. Nauck, F. Stöckmann, R. Ebert, and W. Creutzfeldt Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 1986 46 52 (Pubitemid 16162741)
2. J.E. Gerich Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus Mayo Clinic Proceedings 78 2003 447 456 (Pubitemid 36373946)
3. T. Vilsboll, T. Krarup, S. Madsbad, and J.J. Holst Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients Diabetologia 45 2002 1111 1119 (Pubitemid 34985287)
4. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705 (Pubitemid 46048557)
5. T. Vilsboll, H. Agerso, T. Krarup, and J.J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects Journal of Clinical Endocrinology and Metabolism 88 2003 220 224 (Pubitemid 36115169)
6. ® (exenatide) prescribing information, 2005, Available at: http://pi.lilly.com/us/byetta-pi. pdf (accessed 25.01.11).
7. ® (exenatide ER) summary of product characteristics, 2011, Available at: http://www.medicines. org.uk/EMC/medicine/24665/SPC/BYDUREON+2+mg+powder+and+solvent+for+prolonged- release+suspension+for+injection/ (accessed 11.01.12).
8. H. Agerso, L.B. Jensen, and B. Elbrond The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 2002 195 202 (Pubitemid 34208381)
9. R.E. Pratley, and M. Gilbert Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors The Review of Diabetic Studies 5 2008 73 94
10. T.J. Bell, and E.E. Wright Jr. Can therapies that target the incretin system improve our ability to treat type 2 diabetes? Journal of the National Medical Association 102 2010 511 523
11. B. Ahrén The future of incretin-based therapy: novel avenues - novel targets Diabetes, Obesity and Metabolism 13 2011 158 166
12. J.B. Buse, J. Rosenstock, and G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
13. W.H.H. Sheu, B.J. Hoogwerf, and S.K. Shenouda Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study Diabetologia 54 2011 S38
14. C.F. Deacon, E. Mannucci, B. Ahrén, Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis, Diabetes, Obesity and Metabolism 2012 Apr 3, http://dx.doi.org/ 10.1111/j.1463-1326.2012.01603.x [Epub ahead of print].
15. K. Esposito, D. Cozzolino, and G. Bellastella Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials Diabetes, Obesity and Metabolism 13 2011 594 603
16. R. Pratley, M. Nauck, and T. Bailey One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial International Journal of Clinical Practice 65 2011 397 407
17. D.J. Drucker, J.B. Buse, and K. Taylor Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
18. T. Vilsboll, M. Christensen, and A.E. Junker Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 d7771
19. M.A. Nauck, N. Kleine, and C. Orskov Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744 (Pubitemid 23218642)
20. M.A. Nauck, M.M. Heimesaat, and K. Behle Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers Journal of Clinical Endocrinology and Metabolism 87 2002 1239 1246 (Pubitemid 36121094)
21. A.H. Barnett The incretin system and type 2 diabetes US Endocrinology 5 2010 57 62
22. M.J. Willemen, A.K. Mantel-Teeuwisse, and S.M. Straus Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase Diabetes Care 34 2011 369 374
23. K.R. Richard, J.S. Shelburne, and J.K. Kirk Tolerability of dipeptidyl peptidase-4 inhibitors: a review Clinical Therapeutics 33 2011 1609 1629
24. R. Bergenstal, G. Daniels, and J. Mann Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome Results (LEADER™) trial: rationale and study design Diabetes 60 2011 A612
25. M. Elashoff, A.V. Matveyenko, and B. Gier Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 141 2011 150 156
26. European Association for the Study of Diabetes. EASD commentary on the publication by Elashoff et al., published online in Gastroenterology, February 2011: increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1-based therapy, Available at: http://www.easd.org/ easdwebfiles/statements/Elashoff-Commentary.pdf (accessed 11.01.11).
27. D.J. Drucker, S.I. Sherman, R.M. Bergenstal, and J.B. Buse The safety of incretin-based therapies - review of the scientific evidence Journal of Clinical Endocrinology and Metabolism 96 2011 2027 2031
28. F.X. Pi-Sunyer The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus Postgraduate Medicine 121 2009 94 107
29. F.B. Hu, J.E. Manson, and M. Stampfer Diet, lifestyle, and the risk of type 2 diabetes mellitus in women New England Journal of Medicine 345 2001 790 797
30. K. Eeg-Olofsson, J. Cederholm, and P.M. Nilsson Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients Diabetologia 52 2009 65 73
31. Y. Handelsman, J.I. Mechanick, and L. Blonde American association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan Endocrine Practice 17 2011 1 53
32. S. Klein, N.F. Sheard, and X. Pi-Sunyer Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Diabetes Care 27 2004 2067 2073 (Pubitemid 38989258)
33. D. Russell-Jones, and R. Khan Insulin-associated weight gain in diabetes - causes, effects and coping strategies Diabetes, Obesity and Metabolism 9 2007 799 812 (Pubitemid 47555203)
34. J.J. Holst, C.F. Deacon, and T. Vilsboll Glucagon-like peptide-1, glucose homeostasis and diabetes Trends in Molecular Medicine 14 2008 161 168
35. D.S. Shyangdan, P. Royle, and C. Clar Glucagon-like peptide analogues for type 2 diabetes mellitus Cochrane Database of Systematic Reviews 10 2011 CD006423
36. R.M. Bergenstal, C. Wysham, and L. Macconell Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 2010 431 439
37. A. Astrup, S. Rössner, and L. Van Gaal Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
38. J. Rosenstock, L.J. Klaff, and S. Schwartz Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes Diabetes Care 33 2010 1173 1175